DHT, DHT Intensol
Classifications: vitamin d; serum calcium regulator; Therapeutic: vitamin d
Pregnancy Category: C
0.125 mg, 0.2 mg, 0.4 mg tablets; 0.2 mg/mL oral solution
Oil-soluble reduction product of ergocalciferol (vitamin D2) with pharmacologic actions similar to those of both ergocalciferol and parathyroid hormone. In comparison with ergocalciferol,
dihydrotachysterol promotes less intestinal absorption of calcium but almost equal phosphate diuresis.
Acts like parathyroid hormone in ability to raise serum calcium concentrations rapidly; also reported to increase intestinal
absorption of sodium, potassium, and magnesium.
Hypocalcemia associated with hypoparathyroidism, both postoperative and idiopathic, and in pseudohypoparathyroidism. Also
for prophylaxis of hypocalcemic tetany following thyroid surgery.
Vitamin D-resistant rickets (familial hypophosphatemia), osteoporosis, and renal osteodystrophy.
Sensitivity to vitamin D; hypercalcemia and hypocalcemia associated with renal insufficiency and hyperphosphatemia; renal
stones, hypervitaminosis D; pregnancy (category C). Safe use in children in amounts exceeding RDA is not established.
Cardiac disease, arteriosclerosis; hyperphosphatemia; renal disease; sarcoidosis; lactation.
Route & Dosage
Adult: PO 0.752.5 mg/d for several days, then 0.21 mg/d (may need 1.5 mg/d)
Child: PO 15 mg/d for 4 d, then 0.51.5 mg/d
Neonate: PO 0.050.1 mg/d
Adult: PO 0.25 mg/d
Adult: PO 0.10.6 mg/d
Child: PO 0.10.5 mg/d
- Withhold drug if signs and symptoms of hypercalcemia appear (see Appendix F) and report to physician.
- Store in tightly closed, light-resistant containers at 15°30° C (59°86° F) unless otherwise
Adverse Effects (≥1%)CNS:
Drowsiness, headache, weakness, vertigo, ataxia, atonia, mental depression
Anorexia, nausea, vomiting, metallic taste, dry mouth, thirst, diarrhea
, abdominal pain. Urogenital:
Nocturia, polyuria, renal
calculi. Special Senses:
Readily from small intestines. Peak:
2 wk. Duration:
2 wk. Distribution:
Distributed in breast milk. Metabolism:
In liver to active metabolite
Primarily in bile and feces.
Assessment & Drug Effects
- Lab tests: serum and urinary calcium levels at least weekly during first month of therapy until they are stabilized, then
- Supplement with 1015 g of oral calcium lactate or gluconate daily; adequate calcium intake is necessary for clinical
response to therapy.
- Restrict dietary phosphate or administer calcium carbonate supplements with meals, or both, to bind intestinal phosphates
and improve calcium balance in patients with hyperphosphatemia.
- Monitor hypoparathyroid patients receiving thiazide diuretics closely; they are prone to develop hypercalcemia.
Patient & Family Education
- Learn S&S of hypercalcemia (see Appendix F).